跳至主要内容
临床试验/NCT06931275
NCT06931275招募中不适用

Implementing Best Practice Advisories to Reduce Inequities in Technology Use for People With Type 1 Diabetes

T1D Exchange, United States3 个研究点 分布在 1 个国家目标入组 1,178 人开始时间: 2024年8月13日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
1,178
试验地点
3
主要终点
Progression of Advanced Diabetes Technology use

研究概览

简要总结

The overall goal of the study is to create a standardized, stakeholder-informed system within EMRs, that will enable an equitable and regular prescription and documentation of advanced diabetes technologies. This will reduce racial disparities and generate an understanding of the reasons behind prescription decisions.

The study will highlight the development and implementation an EMR-based Best Practice Advisory (BPA).

The study will answer whether the EMR-based BPA can effectively reduce disparities. Additionally, it will explore why providers may not prescribe advanced diabetes technologies.

Patients will also be surveyed to understand their perspectives on developing the EMR-based BPA.

详细描述

For the proposed study we intend to implement an automatically delivered center decision support system provided at the time and location of the decision making along with actionable recommendations and computer based actionable recommendations. The provider will be required to opt out if not prescribing ADT and to provide a reason for not prescribing in order to advance on the EMR screen (Kawamoto et al, 2015).

Project Objectives Aim 1: To develop and implement an EMR-based BPA using stakeholder feedback to standardize the approach for prescribing and documentation of advanced diabetes technologies (ADT) (CGM, insulin pump, AID) among adult and pediatric PwT1D.

Aim 2: To determine the effectiveness of an EMR-based BPA in reducing racial inequities in ADT.

Primary Objective: To compare the proportion of non-white (non-Hispanic Black and Hispanic) PwT1D with progression in ADT use (CGM, insulin pump, AID) at 6 centers in the T1DX-QI (3 pediatric and 3 adult centers) where the BPA intervention is implemented with matched control non-white PwT1D at T1DX-QI centers not receiving the intervention over a 12-month period, adjusting for baseline level of ADT use and other confounders.

Secondary Objective: To assess the difference in ADT use between White and non-white (non-Hispanic Black and Hispanic) PwT1D receiving care at the intervention centers compared with the racial difference in ADT use in matched control PwT1D.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Health Services Research
盲法
None

入排标准

年龄范围
2 Years 至 95 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age ≥ 2 years with an EMR diagnosis of T1D for at least 6 months at baseline and receiving care at one of six intervention centers or a matched control at another T1DX-QI center.
  • Inclusion Criteria:
  • non-Hispanic Black and Hispanic individuals

排除标准

  • PwT1D with evidence of use of AID at baseline

结局指标

主要结局

Progression of Advanced Diabetes Technology use

时间窗: 12 months

Defined as positive for an individual if: • MDI/smartpen + no CGM begins using CGM * MDI/smartpen + CGM begins using insulin pump * Insulin pump + no CGM begins using CGM * Insulin pump + CGM (without AID) begins using AID

次要结局

未报告次要终点

研究者

发起方
T1D Exchange, United States
申办方类型
Other
责任方
Principal Investigator
主要研究者

Osagie Ebekozien

MD,

T1D Exchange, United States

研究点 (3)

Loading locations...

相似试验

Best Practice Advisories to Reduce Inequities in... | 临床试验